Can urinary biomarkers help address some of the key limitations of cystoscopy and urine cytology in the surveillance of non-muscle-invasive bladder cancer (NMIBC)?
Watch this expert presentation to discover how urinary biomarkers may support a more patient-centred and efficient approach to NMIBC surveillance.
In this BLADDR 2025 lecture, Dr. Félix Guerrero-Ramos reviews the growing evidence supporting the use of urinary biomarkers in NMIBC follow-up. Drawing on recent clinical studies and real-world data, he discusses the challenges of current surveillance strategies, including the burden of repeated cystoscopy, patient discomfort, missed carcinoma in situ (CIS), and increasing pressure on healthcare resources.
The presentation explores the performance of established and emerging urinary biomarkers, with a particular focus on their potential to reduce unnecessary cystoscopies, improve detection of high-grade disease, and complement advanced imaging techniques such as blue-light cystoscopy. Dr. Félix Guerrero-Ramos also examines the economic implications of biomarker-guided surveillance and shares insights into novel molecular approaches that may further transform bladder cancer monitoring in the future.